• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MANUFACTURING INC CLINICAL CHEMISTRY LACTATE DEHYDROGENASE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MANUFACTURING INC CLINICAL CHEMISTRY LACTATE DEHYDROGENASE Back to Search Results
Catalog Number 02P56-21
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 02/28/2019
Event Type  malfunction  
Manufacturer Narrative
An evaluation is in process.A final report will be submitted when the evaluation is complete.
 
Event Description
The account generated false elevated architect ldh results on id (b)(6) of 558, 184 and 256 u/l.The account uses a normal ldh range of 125 to 220 u/l.No impact to patient management was reported.No specific patient information was provided.
 
Manufacturer Narrative
Quality control results were reported as ok when a precision run was done.A review of the ldh qc results for (b)(6) to (b)(6) 2019 show within control assay precision.No atypical complaint trends or non-conformance were identified related for the ldh assay results.The ldh assay package insert has extensive information on the need for correct sample preparation.For plasma samples, sufficient centrifugation is necessary to remove platelets and other cellular materials that may impact ldh results.Plasma samples may benefit from the 1:3 dilution provided in the assay parameter file to help decrease the impact of platelets on ldh analyses.To optimize plasma analysis, the package insert states samples may be transferred to a secondary sample tube after centrifugation.Based on the complaint information and the package insert labeling, the most likely cause for the initially elevated ldh results are related to the sample preparation process.The labeling describes cellular debris or platelets as having a likely impact to patient results.With qc material lacking these components, there would be no impact on those samples.Use error may have contributed to the customer issue as insufficient sample collection or preparation is a likely cause of the initially elevated sample results.Trend review and lot search did not identify an increase in complaint activity for the current issue.No customer returns were available for evaluation.No product deficiency was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CLINICAL CHEMISTRY LACTATE DEHYDROGENASE
Type of Device
LACTATE DEHYDROGENASE
Manufacturer (Section D)
ABBOTT MANUFACTURING INC
1921 hurd drive
irving TX 75038
MDR Report Key8442431
MDR Text Key139713841
Report Number1628664-2019-00237
Device Sequence Number1
Product Code CFJ
UDI-Device Identifier00380740004033
UDI-Public00380740004033
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 07/16/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date08/08/2019
Device Catalogue Number02P56-21
Device Lot Number38576UN18
Was Device Available for Evaluation? Yes
Initial Date Manufacturer Received 02/28/2019
Initial Date FDA Received03/21/2019
Supplement Dates Manufacturer Received06/20/2019
Supplement Dates FDA Received07/16/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARCHITECT C8000, LN 01G06-11; ARCHITECT C8000, LN 01G06-11; SERIAL (B)(6); SERIAL (B)(6)
-
-